Hospital
SSM Health Care ST. Louis
SSM Health Care ST. Louis was paid $27.71M by Medicaid between Jan 2018 and Dec 2024, across 137 billing codes. Its largest line is X4011, State-specific procedure code — 25% of everything it billed.
33Billing provider infoSSM HEALTH CARE ST. LOUIS
BRIDGETON, MO 63044
BRIDGETON, MO 63044
33aNPI1598835308assigned 11/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.71M
24GClaims322,776
24DCodes billed137
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#14 of 74
Median peer was paid$4.44M
This provider vs. median6.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,477 | $7.30M | |
| 2019 | 37,368 | $4.40M | |
| 2020 | 31,960 | $2.81M | |
| 2021 | 47,972 | $2.14M | |
| 2022 | 55,992 | $3.23M | |
| 2023 | 61,300 | $4.23M | |
| 2024incomplete | 50,707 | $3.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| X4011 | State-specific procedure code | 25% | 26,268 | 23,980 | $7.00M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 11% | 35,989 | 32,975 | $3.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 19,863 | 18,608 | $2.87M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.5% | 13,009 | 12,005 | $2.63M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.1% | 47,120 | 40,336 | $1.70M |
| 80053 | Comprehensive metabolic panel | 5.4% | 39,055 | 34,894 | $1.50M |
| X4003 | 4.7% | 10,900 | 6,991 | $1.32M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 15,548 | 14,041 | $787K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.5% | 2,222 | 1,993 | $705K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 5,697 | 5,222 | $571K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.5% | 3,192 | 2,991 | $416K |
| 81003 | 1.3% | 5,614 | 4,296 | $358K |
125 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 9,973 | $355K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 7,090 | $325K |
| 36902 | 1.2% | 658 | $320K | |
| 84484 | 1.1% | 12,298 | $297K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 1,286 | $264K |
| 81001 | <1% | 3,072 | $244K | |
| G0378 | Hospital observation service, per hour | <1% | 733 | $214K |
| X4006 | <1% | 229 | $205K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,657 | $179K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,394 | $170K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,350 | $165K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,587 | $140K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 901 | $137K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,584 | $132K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,988 | $128K |
| 81002 | <1% | 1,506 | $122K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,512 | $114K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,021 | $109K |
| 81025 | <1% | 1,120 | $101K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,130 | $74K |
| 83690 | <1% | 1,646 | $66K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,823 | $56K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,033 | $56K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 172 | $55K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 899 | $53K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 523 | $52K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,312 | $49K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 445 | $47K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 209 | $45K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 359 | $42K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 291 | $37K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,378 | $33K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,722 | $32K |
| 76818 | <1% | 552 | $31K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 338 | $26K |
| 59025 | Fetal non-stress test | <1% | 90 | $24K |
| 84702 | <1% | 95 | $22K | |
| J3490 | Unclassified drugs | <1% | 3,529 | $21K |
| Y7506 | <1% | 124 | $21K | |
| 87400 | <1% | 622 | $19K | |
| 87428 | <1% | 417 | $16K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 222 | $16K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 197 | $14K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 197 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 422 | $14K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 133 | $14K |
| 86780 | <1% | 415 | $13K | |
| 84703 | <1% | 394 | $13K | |
| 83880 | <1% | 232 | $12K | |
| 85610 | <1% | 196 | $11K | |
| 36591 | <1% | 195 | $11K | |
| 82947 | <1% | 126 | $10K | |
| 85730 | <1% | 89 | $7K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 362 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 36 | $7K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 147 | $7K |
| 96415 | <1% | 202 | $6K | |
| 83735 | <1% | 1,421 | $6K | |
| 64483 | <1% | 29 | $6K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 492 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 131 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 801 | $4K |
| 87081 | <1% | 429 | $4K | |
| 36832 | <1% | 12 | $4K | |
| 36901 | <1% | 13 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 76 | $3K |
| 86850 | <1% | 25 | $3K | |
| 82657 | <1% | 151 | $3K | |
| 76801 | <1% | 41 | $2K | |
| 86592 | <1% | 16 | $2K | |
| 80061 | Lipid panel | <1% | 291 | $2K |
| 86900 | <1% | 24 | $2K | |
| 80055 | <1% | 20 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 457 | $1K |
| 85379 | <1% | 14 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 29 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 259 | $1K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 14 | $1K |
| 0240U | <1% | 16 | $1K | |
| 83020 | <1% | 18 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $1K |
| 87899 | <1% | 87 | $1K | |
| 93985 | <1% | 15 | $995.97 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 46 | $994.53 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 17 | $835.75 |
| 73630 | <1% | 15 | $821.60 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 908 | $718.30 |
| 86901 | <1% | 24 | $697.63 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $483.82 |
| 93990 | <1% | 13 | $389.43 | |
| 84450 | <1% | 127 | $381.58 | |
| 84075 | <1% | 127 | $381.58 | |
| 82247 | <1% | 127 | $370.06 | |
| 82040 | <1% | 127 | $365.18 | |
| 82962 | <1% | 458 | $320.14 | |
| 83605 | <1% | 65 | $300.21 | |
| 82803 | <1% | 21 | $271.05 | |
| 84155 | <1% | 127 | $270.20 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 16 | $230.52 |
| 87040 | <1% | 15 | $152.85 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 18 | $120.96 |
| 86803 | <1% | 38 | $95.57 | |
| 87210 | <1% | 15 | $64.98 | |
| 86696 | <1% | 26 | $61.92 | |
| 86694 | <1% | 26 | $57.55 | |
| 86695 | <1% | 26 | $52.75 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,002 | $48.65 |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 237 | $35.81 |
| 87340 | <1% | 13 | $34.88 | |
| J2704 | Injection, propofol, 10 mg | <1% | 325 | $3.34 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 275 | $2.45 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 89 | $0.05 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 650 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 972 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 42 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 157 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 14 | $0.00 |
| 36600 | 0% | 18 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 13 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 343 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 645 | $0.00 |
| C1769 | Guide wire | 0% | 673 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 133 | $0.00 |
| 36907 | 0% | 72 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 104 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARRISON, TINA (PRESIDENT)
Parent organizationSSM HEALTH CARE CORPORATION
| Provider | Location | Paid |
|---|---|---|
| SSM Health Care ST. Louis | Fenton, MO | $7.68M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.